Dr. Tam on Zanubrutinib Approval in MCL
Publication
Video
Supplements and Featured PublicationsBTK Inhibitors in B-Cell Lymphomas
Volume 1
Issue 1
Constantine S. Tam, MD, MBBS, discusses the FDA approval of zanubrutinib in mantle cell lymphoma.
Constantine S. Tam, MD, MBBS, associate professor, Peter MacCallum Cancer Centre, discusses the FDA approval of zanubrutinib (Brukinsa) in mantle cell lymphoma (MCL).
In November 2019, the FDA granted an accelerated approval to zanubrutinib capsules for the treatment of adult patients with MCL who have received ≥1 prior therapy, explains Tam.
The approval is based on 2 single-arm studies that showed high response rates with the BTK inhibitor. In the open-label, multicenter, phase II BGB-3111-206 trial (NCT03206970) conducted in China, the complete response rate was 59%, which was substantially higher than reports for ibrutinib, Tam concludes.
Articles in this issue
Bruton Tyrosine Kinase Inhibitors in B-Cell Lymphomas
Bruton Tyrosine Kinase Inhibitors in B-Cell Lymphomas
Dr. Ghosh on Approved BTK Inhibitors in B-Cell Malignancies
BTK Inhibitors Revolutionize Treatment in B-Cell Malignancies, But Require AE Awareness
Leslie Breaks Down the Growing Importance of BTK Inhibitors in B-Cell Malignancies
BTK Inhibitors Boost Outcomes in B-Cell Malignancies, But Challenges Remain
Dr. Ma on First- and Second-Generation BTK Inhibitors in B-Cell Malignancies
Dr. Leslie on the Utility of BTK Inhibitors in B-Cell Malignancies
Building on Current Understandings of BTK Inhibition in CLL, MCL
Dr. Burke on Current FDA Indications for BTK Inhibitors in B-Cell Malignancies
Dr. Treon on the Evolution of BTK Inhibitors in Waldenström Macroglobulinemia
Dr. Maddocks on the Role of Zanubrutinib in B-Cell Malignancies
BTK Inhibitors Transform Treatment in CLL, MCL, and Waldenstrom Macroglobulinemia
An Expert Assessment of Available BTK Inhibitors Within the CLL Treatment Spectrum
Exploring the Role of BTK Inhibitors in B-Cell Lymphomas
Related Videos
Related Content
